Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Analysis of Liquidity Ratios
- Price to FCFE (P/FCFE)
- Dividend Discount Model (DDM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Operating Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Current Ratio since 2005
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The solvency position of the company demonstrates a generally strengthening financial structure over the period, with some notable fluctuations in specific metrics. Overall debt levels, as indicated by several ratios, decreased from 2021 to 2023 before experiencing increases in 2024 and 2025. However, the company consistently maintains a low level of debt relative to equity, capital, and assets.
- Debt Levels
- Debt to equity, debt to capital, and debt to assets all exhibited declining trends from 2021 through 2023. This suggests a reduction in financial risk associated with leverage during this timeframe. A reversal of this trend is observed in 2024 and 2025, with ratios increasing, though remaining relatively low. The inclusion of operating lease liabilities consistently results in higher debt ratios compared to those excluding them, highlighting the impact of lease obligations on the company’s reported debt position.
- Leverage Ratios
- Financial leverage remained relatively stable between 2021 and 2023, fluctuating around 1.3. An increase to 1.37 is noted in 2024, holding steady in 2025. This indicates a consistent, though slightly increasing, reliance on financial leverage to amplify returns.
- Coverage Ratios
- Interest coverage experienced a substantial increase from 2021 to 2023, peaking at 100.32 in 2023. A significant decline to 9.12 is observed in 2024, followed by a dramatic increase to 350.11 in 2025. This volatility suggests changes in earnings relative to interest expense. Fixed charge coverage mirrored this trend, increasing through 2023, decreasing sharply in 2024, and then recovering substantially in 2025. The large fluctuations in both coverage ratios warrant further investigation to understand the underlying drivers of these changes.
In summary, the company’s solvency position appears generally healthy, characterized by low debt levels and strong coverage ratios, although the significant fluctuations in interest and fixed charge coverage in 2024 and 2025 require further scrutiny.
Debt Ratios
Coverage Ratios
Debt to Equity
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Current finance lease liabilities | ||||||
| Long-term finance lease liabilities | ||||||
| Total debt | ||||||
| Shareholders’ equity | ||||||
| Solvency Ratio | ||||||
| Debt to equity1 | ||||||
| Benchmarks | ||||||
| Debt to Equity, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Debt to Equity, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Equity, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The debt to equity ratio demonstrates a consistent and significant decline over the five-year period. This indicates a strengthening financial position with decreasing reliance on debt financing relative to equity.
- Debt to Equity Ratio Trend
- In 2021, the debt to equity ratio was 0.06. This decreased to 0.03 in 2022, and continued to fall to 0.02 in 2023. The rate of decline slowed in subsequent years, reaching 0.01 in both 2024 and 2025.
The substantial reduction in total debt, coupled with consistent growth in shareholders’ equity, drives this trend. Total debt decreased from US$556.7 million in 2021 to US$112.2 million in 2025. Simultaneously, shareholders’ equity increased from US$10.1 billion to US$18.7 billion over the same period.
- Implications of the Trend
- The decreasing debt to equity ratio suggests reduced financial risk. The company appears to be increasingly funded by equity rather than debt, potentially lowering interest expenses and increasing financial flexibility. This trend could also be viewed favorably by investors, signaling a more stable and sustainable capital structure.
The stabilization of the ratio at 0.01 in the final two years suggests a potential target capital structure has been reached, or that the pace of debt reduction has intentionally slowed. Further investigation into the company’s capital allocation strategy would be necessary to confirm this.
Debt to Equity (including Operating Lease Liability)
Vertex Pharmaceuticals Inc., debt to equity (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Current finance lease liabilities | ||||||
| Long-term finance lease liabilities | ||||||
| Total debt | ||||||
| Current operating lease liabilities | ||||||
| Long-term operating lease liabilities | ||||||
| Total debt (including operating lease liability) | ||||||
| Shareholders’ equity | ||||||
| Solvency Ratio | ||||||
| Debt to equity (including operating lease liability)1 | ||||||
| Benchmarks | ||||||
| Debt to Equity (including Operating Lease Liability), Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Debt to Equity (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Equity (including Operating Lease Liability), Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The debt to equity ratio, including operating lease liabilities, demonstrates a fluctuating pattern over the five-year period. Initially, the ratio decreased before stabilizing at a higher level in the most recent two years.
- Overall Trend
- From 2021 to 2023, a consistent decrease in the debt to equity ratio is observed. However, beginning in 2023, the ratio increased significantly and remained stable in 2024 and 2025. This suggests a shift in the company’s capital structure towards increased reliance on debt financing in recent periods.
- Detailed Analysis (2021-2023)
- In 2021, the debt to equity ratio stood at 0.10. This decreased to 0.06 in 2022, and further to 0.05 in 2023. This decline coincided with a more rapid increase in shareholders’ equity compared to the decrease in total debt, indicating strengthening financial leverage. The reduction in total debt also contributed to this trend.
- Detailed Analysis (2023-2025)
- From 2023 to 2024, the debt to equity ratio increased from 0.05 to 0.11. This increase is primarily attributable to a substantial rise in total debt, including operating lease liabilities, from US$808.4 million to US$1,749.5 million, while shareholders’ equity experienced a moderate decrease. The ratio remained at 0.11 in 2025, with a further increase in total debt to US$2,036.0 million and a corresponding increase in shareholders’ equity. This suggests that while the company is taking on more debt, it is also increasing its equity base, maintaining the ratio at the 2024 level.
- Key Observations
- The recent increase in the debt to equity ratio warrants attention. While the company maintains a substantial equity base, the growing debt levels could potentially increase financial risk. The consistent ratio in the last two years suggests a deliberate strategy to maintain a certain level of debt financing, potentially to fund growth initiatives or capital expenditures.
Debt to Capital
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Current finance lease liabilities | ||||||
| Long-term finance lease liabilities | ||||||
| Total debt | ||||||
| Shareholders’ equity | ||||||
| Total capital | ||||||
| Solvency Ratio | ||||||
| Debt to capital1 | ||||||
| Benchmarks | ||||||
| Debt to Capital, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Debt to Capital, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Capital, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The debt to capital ratio demonstrates a consistent and significant decline over the five-year period. This indicates a decreasing reliance on debt financing relative to the company’s total capital structure.
- Debt to Capital Ratio Trend
- The ratio decreased from 0.05 in 2021 to 0.01 in both 2024 and 2025. This represents a substantial reduction in leverage.
The magnitude of the decrease is noteworthy. The ratio more than halved from 2021 to 2022, and continued to fall steadily through 2023 before stabilizing at 0.01 in the final two years of the observed period. This suggests proactive debt management or a shift towards equity-based financing.
- Total Debt
- Total debt decreased from US$556.7 million in 2021 to US$112.2 million in 2025. The most significant reduction occurred between 2021 and 2023, with a more moderate decrease from 2023 to 2025.
- Total Capital
- Total capital increased from US$10.66 billion in 2021 to US$18.78 billion in 2025. While there was a slight decrease between 2022 and 2023, the overall trend is upward, indicating growth in the company’s capital base.
The combined effect of decreasing debt and increasing total capital is the observed decline in the debt to capital ratio. This suggests a strengthening financial position and reduced financial risk.
Debt to Capital (including Operating Lease Liability)
Vertex Pharmaceuticals Inc., debt to capital (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Current finance lease liabilities | ||||||
| Long-term finance lease liabilities | ||||||
| Total debt | ||||||
| Current operating lease liabilities | ||||||
| Long-term operating lease liabilities | ||||||
| Total debt (including operating lease liability) | ||||||
| Shareholders’ equity | ||||||
| Total capital (including operating lease liability) | ||||||
| Solvency Ratio | ||||||
| Debt to capital (including operating lease liability)1 | ||||||
| Benchmarks | ||||||
| Debt to Capital (including Operating Lease Liability), Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Debt to Capital (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Capital (including Operating Lease Liability), Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= ÷ =
2 Click competitor name to see calculations.
The Debt to Capital ratio, inclusive of operating lease liabilities, demonstrates a fluctuating pattern over the five-year period. Initially, the ratio decreased before increasing again in later years. A review of the underlying components reveals insights into these movements.
- Overall Trend
- From 2021 to 2023, a consistent downward trend in the Debt to Capital ratio is observed, decreasing from 0.09 to 0.04. This indicates a decreasing reliance on debt financing relative to the company’s total capital structure during this period. However, from 2023 to 2025, the ratio increased to 0.10, suggesting a shift towards greater debt utilization.
- Debt Component
- Total debt, including operating lease liability, decreased from US$967.4 million in 2021 to US$808.4 million in 2023. This decline contributed to the initial decrease in the Debt to Capital ratio. However, a substantial increase in total debt is then noted, rising to US$1,749.5 million in 2024 and further to US$2,036.0 million in 2025. This increase is the primary driver of the ratio’s subsequent rise.
- Capital Component
- Total capital, inclusive of operating lease liability, exhibited a consistent upward trend from 2021 to 2025, increasing from US$11,067.4 million to US$20,701.8 million. While the increase in debt in 2024 and 2025 was significant, the concurrent growth in total capital partially offset the impact on the Debt to Capital ratio, preventing a more substantial increase.
The stabilization of the Debt to Capital ratio at 0.10 in 2024 and 2025 suggests a potential equilibrium point in the company’s capital structure, given the observed increases in both debt and total capital. Further investigation into the reasons behind the debt increases in 2024 and 2025 would be beneficial to understand the long-term implications for the company’s financial risk profile.
Debt to Assets
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Current finance lease liabilities | ||||||
| Long-term finance lease liabilities | ||||||
| Total debt | ||||||
| Total assets | ||||||
| Solvency Ratio | ||||||
| Debt to assets1 | ||||||
| Benchmarks | ||||||
| Debt to Assets, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Debt to Assets, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Assets, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The Debt to Assets ratio demonstrates a consistent and significant decline over the five-year period. This indicates a decreasing reliance on debt financing relative to the company’s total asset base.
- Debt to Assets Ratio Trend
- The ratio decreased from 0.04 in 2021 to 0.00 in 2025. This represents a substantial reduction in financial leverage.
The magnitude of the decrease is noteworthy. The ratio halved from 0.04 to 0.02 between 2021 and 2023, and then continued to decline, reaching zero by 2025. This suggests a deliberate strategy to reduce debt or a significant increase in asset values relative to debt.
- Total Debt
- Total debt decreased from US$556.7 million in 2021 to US$112.2 million in 2025. The most substantial reduction occurred between 2022 and 2024, decreasing from US$471.6 million to US$118.0 million.
- Total Assets
- Total assets increased steadily from US$13.43 billion in 2021 to US$25.64 billion in 2025. This growth in assets, coupled with the decreasing debt, contributes to the declining Debt to Assets ratio.
The ratio reaching zero in 2025 signifies that, based on these figures, the company’s assets are entirely financed by equity or retained earnings. This could indicate a strong financial position and reduced financial risk.
Debt to Assets (including Operating Lease Liability)
Vertex Pharmaceuticals Inc., debt to assets (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Current finance lease liabilities | ||||||
| Long-term finance lease liabilities | ||||||
| Total debt | ||||||
| Current operating lease liabilities | ||||||
| Long-term operating lease liabilities | ||||||
| Total debt (including operating lease liability) | ||||||
| Total assets | ||||||
| Solvency Ratio | ||||||
| Debt to assets (including operating lease liability)1 | ||||||
| Benchmarks | ||||||
| Debt to Assets (including Operating Lease Liability), Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Debt to Assets (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Assets (including Operating Lease Liability), Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The Debt to Assets ratio, including operating lease liability, demonstrates a fluctuating pattern over the five-year period. Initially, the ratio decreased before increasing again in later years. A review of the underlying components, Total Debt and Total Assets, provides further context for these movements.
- Overall Trend
- From 2021 to 2023, the Debt to Assets ratio exhibited a consistent decline, moving from 0.07 to 0.04. This indicates a decreasing reliance on debt financing relative to the company’s asset base. However, beginning in 2023, the ratio reversed course, increasing to 0.08 in both 2024 and 2025. This suggests a shift towards increased debt utilization or slower asset growth in recent periods.
- Total Debt Analysis
- Total debt, including operating lease liability, decreased from US$967.4 million in 2021 to US$808.4 million in 2023. This decline contributed to the initial decrease in the Debt to Assets ratio. However, a substantial increase in total debt is observed in 2024, reaching US$1,749.5 million, and continuing to US$2,036.0 million in 2025. This significant rise in debt levels is the primary driver of the ratio’s subsequent increase.
- Total Assets Analysis
- Total assets increased steadily from US$13,432.5 million in 2021 to US$22,730.2 million in 2023. This asset growth, coupled with the declining debt, contributed to the improving Debt to Assets ratio during this period. While assets experienced a slight decrease in 2024 to US$22,533.2 million, they resumed growth in 2025, reaching US$25,643.0 million. However, the rate of asset growth appears insufficient to offset the substantial increase in debt observed in the latter two years.
The recent increase in the Debt to Assets ratio warrants further investigation. While the company’s asset base continues to expand, the more rapid growth of debt suggests a potential increase in financial leverage and associated risk. Monitoring this trend in future periods will be crucial to assess the company’s long-term solvency.
Financial Leverage
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Total assets | ||||||
| Shareholders’ equity | ||||||
| Solvency Ratio | ||||||
| Financial leverage1 | ||||||
| Benchmarks | ||||||
| Financial Leverage, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Financial Leverage, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Financial Leverage, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The financial leverage of the company, as indicated by the provided figures, demonstrates a relatively stable pattern over the five-year period from 2021 to 2025. Total assets increased consistently throughout the period, while shareholders’ equity also generally increased, though with a slight decrease in 2024.
- Financial Leverage Trend
- The financial leverage ratio exhibited a slight decrease from 1.33 in 2021 to 1.29 in 2022 and remained at 1.29 in 2023. A modest increase was then observed in 2024, rising to 1.37, and remained constant at 1.37 in 2025. This suggests a slight increase in the reliance on debt financing towards the end of the analyzed period, although the change is not substantial.
The consistent growth in total assets, coupled with the generally increasing shareholders’ equity, suggests a healthy expansion of the company’s asset base funded by both debt and equity. The slight dip in shareholders’ equity in 2024 did not significantly impact the overall leverage ratio, indicating a continued ability to manage its financial structure. The stabilization of the financial leverage ratio in the final two years suggests a deliberate effort to maintain a consistent capital structure.
- Asset and Equity Growth
- Total assets grew from US$13,432,500 thousand in 2021 to US$25,643,000 thousand in 2025, representing a significant overall increase. Shareholders’ equity followed a similar upward trend, increasing from US$10,100,000 thousand to US$18,665,800 thousand over the same period. The decrease in shareholders’ equity in 2024, from US$17,580,400 thousand to US$16,409,600 thousand, warrants further investigation, but did not materially alter the overall financial leverage position.
In conclusion, the company maintains a moderate level of financial leverage, which has remained relatively stable despite asset and equity growth. The slight increase in leverage in the final two years of the period is not substantial and appears to be managed within acceptable parameters.
Interest Coverage
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net income (loss) | ||||||
| Add: Income tax expense | ||||||
| Add: Interest expense | ||||||
| Earnings before interest and tax (EBIT) | ||||||
| Solvency Ratio | ||||||
| Interest coverage1 | ||||||
| Benchmarks | ||||||
| Interest Coverage, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Interest Coverage, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Interest Coverage, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Interest coverage = EBIT ÷ Interest expense
= ÷ =
2 Click competitor name to see calculations.
The interest coverage ratio exhibits significant fluctuation over the observed period. Initial values demonstrate a strong ability to meet interest obligations, followed by a substantial decline and subsequent recovery.
- Overall Trend
- The interest coverage ratio increased from 45.40 in 2021 to a peak of 100.32 in 2023, indicating a strengthening capacity to cover interest expenses with earnings. However, a dramatic decrease to 9.12 occurred in 2024, before a substantial rebound to 350.11 in 2025.
- EBIT Contribution
- Earnings before interest and tax generally increased from 2021 to 2023, contributing to the improved interest coverage. The significant drop in EBIT in 2024 directly correlates with the decline in the interest coverage ratio for that year. The recovery in EBIT in 2025 is mirrored by the substantial increase in the interest coverage ratio.
- Interest Expense Impact
- Interest expense decreased consistently from 2021 to 2025. While this trend would typically support an improving interest coverage ratio, the impact of this decrease was overshadowed by the substantial fluctuation in EBIT. The largest decrease in interest expense occurred between 2024 and 2025, coinciding with the most significant increase in the interest coverage ratio.
The volatility in the interest coverage ratio, particularly the sharp decline in 2024, warrants further investigation into the underlying factors affecting earnings before interest and tax. Despite the generally decreasing trend in interest expense, the company’s ability to comfortably cover its interest obligations is heavily dependent on its operational profitability.
Fixed Charge Coverage
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net income (loss) | ||||||
| Add: Income tax expense | ||||||
| Add: Interest expense | ||||||
| Earnings before interest and tax (EBIT) | ||||||
| Add: Operating lease cost | ||||||
| Earnings before fixed charges and tax | ||||||
| Interest expense | ||||||
| Operating lease cost | ||||||
| Fixed charges | ||||||
| Solvency Ratio | ||||||
| Fixed charge coverage1 | ||||||
| Benchmarks | ||||||
| Fixed Charge Coverage, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Fixed Charge Coverage, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Fixed Charge Coverage, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Fixed charge coverage = Earnings before fixed charges and tax ÷ Fixed charges
= ÷ =
2 Click competitor name to see calculations.
The company demonstrates a fluctuating ability to cover its fixed charges over the five-year period. Initially, a strong and increasing coverage is observed, followed by a significant decline, and then a recovery.
- Earnings Before Fixed Charges and Tax
- Earnings before fixed charges and tax increased substantially from 2021 to 2022, and continued to rise modestly in 2023. A dramatic decrease is evident in 2024, followed by a substantial recovery in 2025, returning to levels comparable to those seen in 2023.
- Fixed Charges
- Fixed charges remained relatively stable between 2021 and 2023, experiencing a slight decrease in 2022. A notable increase in fixed charges occurred in 2024, and this trend continued into 2025, representing the highest level of fixed charges over the observed period.
- Fixed Charge Coverage
- The fixed charge coverage ratio exhibited a strong upward trend from 2021 to 2023, increasing from 29.62 to 48.66. This indicates a progressively improving ability to meet fixed obligations. However, the ratio experienced a precipitous decline in 2024, falling to 2.85, suggesting a significantly weakened capacity to cover fixed charges. The ratio rebounded considerably in 2025, reaching 23.32, indicating a restored, though not fully recovered, ability to meet fixed obligations.
The substantial decrease in fixed charge coverage in 2024 appears to be driven by a combination of significantly lower earnings before fixed charges and tax, and increased fixed charges. The recovery in 2025 is attributable to a substantial increase in earnings before fixed charges and tax, partially offsetting the continued increase in fixed charges.